针对结肠癌蛋白质组的血清免疫反应性会随疾病进展而变化。
Serological immunoreactivity against colon cancer proteome varies upon disease progression.
作者信息
De Monte Lucia, Sanvito Francesca, Olivieri Stefano, Viganò Fiammetta, Doglioni Claudio, Frasson Matteo, Braga Marco, Bachi Angela, Dellabona Paolo, Protti Maria Pia, Alessio Massimo
机构信息
Proteome Biochemistry, Tumor Immunology, Mass Spectrometry, Pathology, Surgery, Experimental Immunology, Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy.
出版信息
J Proteome Res. 2008 Feb;7(2):504-14. doi: 10.1021/pr070360m. Epub 2008 Jan 8.
Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.
利用结肠癌患者的血清，通过筛选二维电泳分离的肿瘤蛋白质组来鉴定肿瘤相关抗原（TAA）。鉴定出一组在结直肠癌中引发血清免疫反应的六种TAA，显示患者体内B细胞对抗原的识别随结肠癌进展而发生改变。与正常黏膜相比，这些蛋白质在肿瘤中的表达要么局限要么增加。
Zotero 插件